Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elastic
ESTC
|
+$386M |
| 2 |
Mercado Libre
MELI
|
+$307M |
| 3 |
Nu Holdings
NU
|
+$265M |
| 4 |
Shopify
SHOP
|
+$254M |
| 5 |
Roblox
RBLX
|
+$253M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beyond Meat
BYND
|
+$232M |
| 2 |
Li Auto
LI
|
+$219M |
| 3 |
Illumina
ILMN
|
+$187M |
| 4 |
Albemarle
ALB
|
+$178M |
| 5 |
Ferrari
RACE
|
+$147M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 29.03% |
| 2 | Healthcare | 24.31% |
| 3 | Technology | 16.9% |
| 4 | Communication Services | 11.22% |
| 5 | Financials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Charles River Laboratories
CRL
$12.8B
| $14.2M | 0.01% |
71,899
+56,103
| +355% | +$12.1M |
|
202
StoneCo
STNE
$2.58B
| $13.8M | 0.01% |
1,443,026
+34,884
| +2% | +$334K |
|
|
MASI
203
DELISTED
Masimo
MASI
| $13.2M | 0.01% |
93,634
+4,162
| +5% | +$608K |
|
204
Tandem Diabetes Care
TNDM
$1.56B
| $12.6M | 0.01% |
263,084
-43,139
| -14% | -$2.37M |
|
205
Burford Capital
BUR
$971M
| $12.1M | 0.01% |
1,623,145
-51,362
| -3% | -$488K |
|
206
Stratasys
SSYS
$774M
| $11.6M | 0.01% |
805,904
-64,551
| -7% | -$1.15M |
|
207
TJX Companies
TJX
$178B
| $11M | 0.01% |
177,210
-4,076
| -2% | -$256K |
|
208
CEVA Inc
CEVA
$1.08B
| $10.8M | 0.01% |
410,994
-68,478
| -14% | -$2.2M |
|
|
CELL
209
DELISTED
PhenomeX Inc. Common Stock
CELL
| $10.6M | 0.01% |
3,718,200
+39,216
| +1% | +$167K |
|
210
QuantumScape Corp
QS
$3.74B
| $10.6M | 0.01% |
1,262,341
+346,060
| +38% | +$3.71M |
|
211
Digimarc Corp
DMRC
$178M
| $10.6M | 0.01% |
780,637
-47,129
| -6% | -$762K |
|
|
AKLI
212
DELISTED
Akili Inc
AKLI
| $10.5M | 0.01% |
+4,665,795
| New | +$33.5M |
|
213
LivePerson
LPSN
$32.3M
| $10.5M | 0.01% |
74,521
-4,257
| -5% | -$816K |
|
214
Sutro Biopharma
STRO
$421M
| $10.4M | 0.01% |
186,862
+344
| +0.2% | +$20.4K |
|
215
Cardlytics
CDLX
$21.5M
| $10.3M | 0.01% |
109,897
-4,194
| -4% | -$597K |
|
216
Butterfly Network
BFLY
$2.35B
| $9.77M | 0.01% |
2,078,788
+37,819
| +2% | +$200K |
|
217
Visa
V
$677B
| $9.33M | 0.01% |
52,499
| – | – |
|
218
Ascendis Pharma A/S
ASND
$16.8B
| $9.14M | 0.01% |
88,497
+2,697
| +3% | +$256K |
|
|
KDNY
219
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $9.13M | 0.01% |
464,314
-40,511
| -8% | -$813K |
|
220
Sherwin-Williams
SHW
$89.8B
| $9.1M | 0.01% |
44,453
| – | – |
|
221
EverQuote
EVER
$906M
| $9.07M | 0.01% |
1,330,065
-47,261
| -3% | -$443K |
|
222
Relay Therapeutics
RLAY
$4.33B
| $9.05M | 0.01% |
404,620
+184,998
| +84% | +$4.06M |
|
223
Zillow
ZG
$7.63B
| $9.05M | 0.01% |
316,059
-28,418
| -8% | -$991K |
|
224
XP
XP
$8.39B
| $8.82M | 0.01% |
464,136
+6,192
| +1% | +$123K |
|
225
Bumble
BMBL
$373M
| $8.6M | 0.01% |
400,000
| – | – |
|
Similar funds
Baillie Gifford & Co's Q3 2022 Portfolio in Review
As of Q3 2022, Baillie Gifford & Co held 506 positions worth $97B, down 0.53% from $97.5B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Baillie Gifford & Co's Q3 2022 filing shows 13 new, 130 increased, 158 reduced and 20 closed positions. Its largest new stake was Elastic: 4,847,733 shares worth $348M. The largest sale was Beyond Meat, an estimated $232M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q3 2022 buy was Elastic: 4,847,733 shares worth $348M.
- Baillie Gifford & Co added most to Mercado Libre in Q3 2022, an estimated $307M increase.
- Baillie Gifford & Co's biggest Q3 2022 reduction was Beyond Meat, cutting an estimated $232M.
- Baillie Gifford & Co fully exited Zai Lab in Q3 2022, selling an estimated $25.5M.
- Baillie Gifford & Co's ten largest holdings make up 37% of its $97B portfolio in Q3 2022.
- Baillie Gifford & Co opened 13 new positions and closed 20 in Q3 2022.
- Baillie Gifford & Co's portfolio value fell 0.53% quarter-over-quarter to $97B.
Based on Baillie Gifford & Co's 13F filing for Q3 2022, filed 27 Oct 2022.